false
0001855644
0001855644
2024-04-08
2024-04-08
0001855644
us-gaap:CommonClassAMember
2024-04-08
2024-04-08
0001855644
us-gaap:WarrantMember
2024-04-08
2024-04-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Warrants [Member]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section
13 or 15(d)
of the
Securities Exchange
Act of 1934
April 8, 2024
Date of Report (Date of earliest event reported)
Zura
Bio Limited
(Exact Name of Registrant as Specified in its
Charter)
Cayman Islands |
|
001-40598 |
|
98-1725736 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
1489 W. Warm Springs Rd. #110
Henderson, NV 89014
(Address of principal executive
offices, including zip code)
(702) 757-6133
(Registrant’s telephone
number, including area code)
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Class A Ordinary Shares, par value $0.0001 per share |
|
ZURA |
|
The Nasdaq Stock Market |
Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share |
|
ZURAW |
|
The Nasdaq Stock Market |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 7.01. |
Regulation FD Disclosure. |
On April
8, 2024, Zura Bio Limited issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
The
information set forth in this Item 7.01 is intended to be furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 8, 2024
ZURA BIO LIMITED |
|
|
|
By: |
/s/ Kim Davis |
|
|
Kim Davis |
|
|
Chief Legal Officer |
|
Exhibit 99.1
Zura Bio Announces Robert Lisicki as CEO and
Director
| - | Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director |
| - | Recognized as inspirational industry leader with exceptional R&D, commercial and global executive
experience |
| - | Outstanding product development and commercialization track record across a number of leading I&I
therapies spanning nearly 30 years |
Henderson, Nev – April 8, 2024 - Zura
Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies
for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director
of the Board at Zura Bio. The Company previously announced Mr. Lisicki's appointment and the commencement of a seamless transition process
with Founding CEO, Dr. Someit Sidhu. This transition marks a key milestone in the company’s journey towards building a leading
immunology company.
Mr. Lisicki has extensive experience in the pharmaceutical
industry, having held key leadership positions at pharmaceutical organizations of various sizes. "With a successful track record
in strategy, commercial operations, and drug development, Robert is well suited to establish Zura Bio as a leading immunology company.
On behalf of the board, I would like to welcome Robert,” stated Amit Munshi, Chairman of Zura Bio Board of Directors. “I also
appreciate Someit’s visionary leadership, which has been instrumental in shaping the company's trajectory thus far. Someit will
remain involved as a board member, offering continued guidance.”
Commenting on the appointment, Robert Lisicki,
Chief Executive Officer and Director, stated, “I’m thrilled to take on this expanded role, and for the opportunity to lead
such a talented and experienced team. Zura Bio has made great progress toward what I believe is a bright future, and it is exciting to
lead the next chapter of that journey. We are moving into a critical phase of trial execution for tibulizumab in systemic sclerosis and
anticipate multiple external and internal readouts over the next 24 months. I believe the collective group of readouts will further validate
our pipeline and demonstrate the value we aspire to bring to autoimmune disease. Over the course of my career, I’ve worked on multiple
successful autoimmune therapies and from that experience understand the power of the right asset with the right group of passionate leaders.
With our potential indications across our portfolio, I’m eager to drive Zura Bio’s mission forward, delivering exceptional
strategic focus and value to our stakeholders. I would like to thank Dr. Someit Sidhu for his thoughtful partnership and look forward
to working with him in his role as a Board Director.”
ABOUT ROBERT LISICKI
Robert Lisicki is an experienced executive leader with a career spanning
30 years in the biopharmaceutical industry. He recently served as President and Chief Operating Officer of Zura Bio and has been serving
on the boards of Adiso Therapeutics and Cadrenal Therapeutics, Inc. since October 2023 and July 2023, respectively. He served as the Chief
Commercial Officer at Arena Pharmaceuticals from October 2018 to March 2022, a prominent biopharmaceutical company acquired by Pfizer
for $6.7 billion in 2022. At Arena, Mr. Lisicki had accountability for building the company’s global commercial infrastructure and
contributed to its mergers and acquisitions activities totaling nearly $8 billion. Prior to Arena, Mr. Lisicki served as Vice President
and General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this dual role, he led both commercial and developmental
initiatives. His career also includes senior leadership roles as CEO and Board Member, InCarda Therapeutics; CCO, Daiichi Sankyo, Inc.;
and VP, Amgen, with his initial experience in sales and marketing at The Janssen Pharmaceutical Companies of Johnson & Johnson. He
holds a Bachelor of Science degree in Finance and Economics from the State University of New York, Albany, New York.
ABOUT ZURA BIO
Zura Bio is a clinical-stage, multi-asset immunology
company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets
which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab
(ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and
inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
Forward-Looking
Statements
This communication includes “forward-looking
statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.
Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,”
“intend,” “plan,” “may,” “will,” “could,” “should,” “believe,”
“predict,” “potential,” “continue,” “strategy,” “future,” “opportunity,”
“would,” “seem,” “seek,” “outlook” and similar expressions are intended to identify such
forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are
based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results
to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication.
These forward-looking statements in this release include, but are not limited to, statements regarding Zura Bio’s business strategies
and objectives, statements related to Zura Bio’s abilitites to achieve anticipated internal readouts and achieve them in expected
time periods, Zura Bio’s product candidates expected therapeutic potential and statements regarding Zura Bio’s product candidates
ability to proceed into Phase 2 clinical trials. These forward-looking statements are provided for illustrative purposes only and are
not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement
of fact or probability.
Actual events and results are difficult or impossible
to predict and could differ materially from those expressed or implied in such forward-looking statements. You should carefully consider
the risks and uncertainties described in the “Risk Factors” sections of Zura Bio's 10-K for the year ended December 31, 2023
and other filings with the SEC, including: Zura Bio’s expectations regarding product candidates and their related benefits; Zura
Bio’s beliefs regarding potential benefits or limitations of competing products both in development and approved; information regarding
Zura Bio’s vision and strategy; anticipated timing of key events and initiation of Zura Bio’s studies and release of clinical
data; Zura Bio’s expectations regarding the general acceptability and maintenance of our products by regulatory authorities, payors,
physicians, and patients; Zura Bio’s ability to attract and retain key personnel; the accuracy of Zura Bio’s future operating
expenses, capital requirements and needs for additional financing; Zura Bio’s ability to obtain funding for operations, including
funds that may be necessary to complete development of our product candidates; the fact that Zura Bio has not completed any clinical trials
and has no products approved for commercial sale; the fact that Zura Bio has incurred significant losses since inception, and it expects
to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future; Zura Bio’s
ability to renew existing contracts; Zura Bio’s reliance on third-party contract development manufacturing organizations for the
manufacture of clinical materials; Zura Bio’s ability to obtain regulatory approval for our products, and any related restrictions
or limitations of any approved products; Zura Bio’s ability to effectively manage growth and competitive pressures from other companies
worldwide in the therapies in which Zura Bio competes; and litigation and Zura Bio’s ability to adequately protect intellectual
property rights. These risks and uncertainties may be amplified by health epidemics or other unanticipated global disruption events, which
may continue to cause economic uncertainty.Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not
to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Zura Bio gives
no assurance that it will achieve its expectations. Zura Bio does not undertake or accept any obligation to publicly provide revisions
or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, or should circumstances
change, except as otherwise required by securities and other applicable laws.
Contact
Megan K. Weinshank
Head of Investor Relations
IR@zurabio.com
PICTURE:
Robert Lisicki (Chief Executive Officer and Director, Zura Bio)
v3.24.1.u1
Cover
|
Apr. 08, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Apr. 08, 2024
|
Entity File Number |
001-40598
|
Entity Registrant Name |
Zura
Bio Limited
|
Entity Central Index Key |
0001855644
|
Entity Tax Identification Number |
98-1725736
|
Entity Incorporation, State or Country Code |
E9
|
Entity Address, Address Line One |
1489 W. Warm Springs Rd.
|
Entity Address, Address Line Two |
#110
|
Entity Address, City or Town |
Henderson
|
Entity Address, State or Province |
NV
|
Entity Address, Postal Zip Code |
89014
|
City Area Code |
702
|
Local Phone Number |
757-6133
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Class A [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Class A Ordinary Shares, par value $0.0001 per share
|
Trading Symbol |
ZURA
|
Security Exchange Name |
NASDAQ
|
Warrants [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
|
Trading Symbol |
ZURAW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Grafico Azioni JATT Acquisition (NYSE:JATT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni JATT Acquisition (NYSE:JATT)
Storico
Da Giu 2023 a Giu 2024